Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

ASTRAZENECA

(AZN)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations
The feature you requested does not exist. However, we suggest the following feature:

AstraZeneca : Up Over 9% After 4Q Revenue, Core EPS Beats -- Data Talk

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/14/2019 | 02:45pm EST

AstraZeneca PLC Sponsored ADR (AZN) is currently at $39.96, up $3.38 or 9.24%

-- Would be highest close since Nov. 29, 2018, when it closed at $40.21

-- On pace for largest percent increase since April 28, 2014, when it rose 12.16%

-- Earlier Thursday, Astrazeneca said fourth-quarter revenue rose 11% to $6.42 billion, ahead of analysts' expectations of $6.32 billion, based on a FactSet consensus forecast and core earnings per share increased 22% to $1.58 in the fourth quarter. This beat analysts' expectations of $1.48

-- Currently up four of the past six days

-- Up 9.24% month-to-date

-- Up 5.21% year-to-date

-- Up 17.46% from 52 weeks ago (Feb. 15, 2018), when it closed at $34.02

-- All data as of 2:21:06 PM

Source: Dow Jones Market Data, FactSet

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA 0.46% 756.6 Delayed Quote.11.89%
ASTRAZENECA 0.57% 6122 Delayed Quote.3.80%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTRAZENECA
02/14ASTRAZENECA : Up Over 9% After 4Q Revenue, Core EPS Beats -- Data Talk
DJ
02/14LONDON STOCK EXCHANGE : FTSE 100 squeezes out gains; ConvaTec drags midcaps
RE
02/14European shares give up three-month highs after shock U.S. data
RE
02/14LONDON MARKETS: London Stocks Cling To Gains; AstraZeneca Surges On Results
DJ
02/14ASTRAZENECA : Turns a Corner After a Decade of Struggles -- 3rd Update
DJ
02/14EUROPE MARKETS: Trade Optimism Helps European Stocks Shrug Off Growth Fears
DJ
02/14GLOBAL MARKETS LIVE : Google, Airbus, Volkswagen, Cisco…
02/14ASTRAZENECA : New cancer drugs, China give AstraZeneca welcome sales boost
RE
02/14ASTRAZENECA : Set for Growth in 2019 -- Earnings Review
DJ
02/14ASTRAZENECA : 4Q Earnings Snapshot
AQ
More news
Financials ($)
Sales 2019 23 493 M
EBIT 2019 6 206 M
Net income 2019 2 766 M
Debt 2019 14 611 M
Yield 2019 3,51%
P/E ratio 2019 36,50
P/E ratio 2020 25,53
EV / Sales 2019 4,91x
EV / Sales 2020 4,46x
Capitalization 101 B
Chart ASTRAZENECA
Duration : Period :
AstraZeneca Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 82,0 $
Spread / Average Target 3,1%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Shriti Vadera Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA3.80%100 794
JOHNSON & JOHNSON5.66%363 193
PFIZER-3.32%244 412
ROCHE HOLDING LTD.13.83%238 215
NOVARTIS7.85%231 004
MERCK AND COMPANY4.48%207 588